Edition:
United Kingdom

Voyager Therapeutics Inc (VYGR.OQ)

VYGR.OQ on NASDAQ Stock Exchange Global Select Market

15.17USD
15 Oct 2018
Change (% chg)

-- (--)
Prev Close
$15.17
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
144,962
52-wk High
$31.91
52-wk Low
$11.54

Summary

Name Age Since Current Position

Mark Levin

67 2014 Independent Chairman of the Board

G. Andre Turenne

44 2018 President, Chief Executive Officer

Allison Dorval

42 2018 Principal Financial Officer and Principal Accounting Officer

Matthew Ottmer

47 2017 Chief Operating Officer

Dinah Sah

57 2017 Chief Scientific Officer

Bernard Ravina

51 2017 Chief Medical Officer

Glenn Pierce

62 2017 Director

Wendy Dixon

62 2017 Independent Director

James Geraghty

63 2014 Independent Director

Michael Higgins

55 2015 Independent Director

Steven Hyman

65 2015 Independent Director

Perry Karsen

63 2015 Independent Director

Biographies

Name Description

Mark Levin

Mr. Mark J. Levin is Independent Chairman of the Board of the Company. Mr. Levin currently serves as a partner at Third Rock Ventures, LLC, which he co-founded in 2007. Mr. Levin also has served on the boards of directors of privately held life sciences companies NinePoint Medical, Inc., Corvia Medical, Inc., and Fulcrum Therapeutics. He was formerly on the boards of publicly traded life sciences companies Eleven Biotherapeutics, Inc. from September 2008 to November 2014 and Foundation Medicine, Inc. from 2010 to June 2014 and privately held companies Constellation Pharmaceuticals, Inc. and Warp Drive Bio, Inc. Mr. Levin served as founding Chief Executive Officer of Millennium Pharmaceuticals, Inc., a biopharmaceutical company since acquired by Takeda Pharmaceutical Company Limited, from 1993 to 2005. Additionally, Mr. Levin was the co-founder of the life sciences effort of the Mayfield Fund, a global venture capital firm, where he was also the founding Chief Executive Officer of Cell Genesys, Inc. from 1989 to 1991; Tularik Inc., a biotechnology company, from 1991 to 1992, Focal, Inc., a biopharmaceutical company, from 1992 to 1993, and Cytotherapeutics, Inc., a biotechnology company, from 1990 to 1992. Mr. Levin started his career as a process engineer and project leader at Eli Lilly and Company and Genentech, Inc. Mr. Levin received both a B.S. and an M.S. in Chemical and Biochemical Engineering from Washington University. We believe Mr. Levin’s experience working with and serving on the boards of directors of life sciences companies and his experience working in the venture capital industry qualifies him to serve on the Board of Directors.

G. Andre Turenne

Mr. G. Andre Turenne is President, Chief Executive Officer of the Company. He is joining the Company from Sanofi, a pharmaceutical company (“Sanofi”), where he served most recently as Senior Vice President, Global Head, Business Development and Licensing since November 2015. Prior to his appointment to this role, Mr. Turenne held various other positions at Sanofi, including as General Manager of Sanofi Genzyme Australia and New Zealand in 2015 and Vice President, Global Head of Genzyme Strategy and Business Development from 2011 to 2014. Prior to its acquisition by Sanofi, Mr. Turenne served in several business development and commercial operations roles at Genzyme Corporation from 2006 to 2011. Mr. Turenne received a B.A. from Kalamazoo College and an M.B.A. from the Tuck School of Business at Dartmouth.

Allison Dorval

Ms. Allison Dorval is re designated as Principal Financial Officer and Principal Accounting Officer of the company effective June 8, 2018. She has served as the Company’s Vice President of Finance since June 2017 and is a certified public accountant. Prior to joining the Company, Ms. Dorval served as Vice President and Controller of Juniper Pharmaceuticals, Inc., a biopharmaceutical company, from August 2016 to June 2017, and as a consultant at Danforth Advisors, a life sciences consultancy focusing on accounting and financial matters, from September 2015 to August 2016. In connection with her role at Danforth, Ms. Dorval served as interim Chief Financial Officer of medical device companies 480 Biomedical, Inc. and Arsenal Medical, Inc. from December 2015 to August 2016. Prior to her time at Danforth, Ms. Dorval served in several roles at Insulet Corporation, a medical device company, from August 2008 to July 2015, including as Chief Financial Officer from November 2014 to May 2015 and as Vice President and Controller from August 2008 to November 2014. Earlier in her career, Ms. Dorval served in various financial and accounting capacities at iBasis, Inc., a telecommunications company; Digitas Inc., an advertising company; and PricewaterhouseCoopers LLP. Ms. Dorval received a B.S. in Business Administration, with a concentration in Accounting, from the University of Vermont and has completed a graduate-level certificate program in Taxation at Bentley University’s McCallum Graduate School of Business.

Matthew Ottmer

Mr. Matthew P. Ottmer is Chief Operating Officer of the company since September 2017. Prior to joining us, Mr. Ottmer served as the Chief Operating Officer of Momenta Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, from December 2015 to April 2017. Prior to joining Momenta Pharmaceuticals, Mr. Ottmer served as Senior Vice President, Strategy & Emerging Businesses of Biogen from July 2014 to July 2015. Prior to his appointment as Senior Vice President, Mr. Ottmer held various other positions of increasing responsibility at Biogen from 1999 to July 2015 including serving as Senior Vice President, Strategy and Emerging Business from July 2014 to July 2015, head of the Tysabri business from March 2012 to July 2014 and as Chief of Staff to the Chief Executive Officer from October 2010 to March 2012. Mr. Ottmer received a B.A. in Political Science from the University of Michigan and an M.B.A. from Northwestern University’s Kellogg School of Management.

Dinah Sah

Dr. Dinah Sah Ph.D., is Chief Scientific Officer of the Company since January 2017, and was previously our Senior Vice President of Neuroscience beginning in March 2014. Prior to joining us, Dr. Sah served as a biotechnology research and development consultant from February 2012 to March 2014. Previously, Dr. Sah held several positions at Alnylam Pharmaceuticals, Inc. including Vice President of Research from 2010 to 2012, Vice President of Research, CNS and Oncology from 2008 to 2010 and Senior Director of Research from 2005 to 2008. From 1999 to 2005 she worked at Biogen, most recently as Associate Director & Head of Neurobiology. Prior to that, Dr. Sah served as the Associate Director of Neurobiology at Signal Pharmaceuticals from 1997 to 1999. Dr. Sah received a B.S. in Biology from the Massachusetts Institute of Technology and a Ph.D. in Neurobiology from Harvard University, and completed her post-doctoral training at Harvard University’s Department of Neurobiology.

Bernard Ravina

Dr. Bernard Ravina M.D., is Chief Medical Officer of the Company since January 2017, and was previously our Vice President of Clinical Development beginning in March 2014. Prior to joining us, Dr. Ravina was Medical Director in Clinical Development at Biogen from October 2010 to March 2014, where he worked on both small molecule drugs and biologics for the treatment of neurological disorders and was responsible for biomarker and clinical development plans in Parkinson’s disease, stroke and neuropathic pain. Prior to that, Dr. Ravina was an Associate Professor of Neurology, Director of the Movement and Inherited Neurological Disorders Unit and Associate Chair of Neurology at the University of Rochester, School of Medicine from August 2005 to October 2010. Dr. Ravina received a B.S. in Psychology from Columbia University, an M.D. from Johns Hopkins University School of Medicine, and an M.S. in Clinical Epidemiology and Biostatistics from the University of Pennsylvania. He completed his residency training in Neurology and a fellowship in Parkinson’s disease and movement disorders at the Hospital of the University of Pennsylvania.

Glenn Pierce

Dr. Glenn F. Pierce, M.D., Ph.D. serves as Director of the Company. Dr. Pierce serves as entrepreneur-in-residence at Third Rock Ventures, having joined the company in 2016 after more than 30 years of research and development experience working with biotechnology companies. Glenn retired from Biogen in 2014 where he most recently served as Chief Medical Officer leading the hematology, cell and gene therapies division. At Biogen, Glenn spearheaded the initiation of the Humanitarian Aid Collaboration with the World Federation of Hemophilia (WFH), and My Life Our Future, a population-wide genotyping and genomic biobank initiative. Prior to Biogen, Glenn served in small, large, public and private biotech/biopharma firms, including Bayer, Inspiration, Avigen, Selective Genetics and Amgen in the areas of tissue regeneration and hematology. He is the co-author of more than 150 scientific papers and received over 15 patents. He served on the Medical and Scientific Advisory Council, the Board of Directors and was president of the board of the National Hemophilia Foundation during a span of two decades. Glenn also served on the Blood Products Advisory Committee at the FDA and the Committee on Blood Safety and Availability at the U.S. Department of Health and Human Services. He currently serves on the WFH and Global Blood Therapeutics Board of Directors. Glenn received an M.D. and a Ph.D. in immunology, both from Case Western Reserve University in Cleveland, and completed his postgraduate training in pathology and hematology research at Washington University in St. Louis.

Wendy Dixon

Dr. Wendy L. Dixon, Ph.D. is an Independent Director of the Company. From 2010 to 2012, she was a senior advisor to The Monitor Group, now Monitor Deloitte, the global strategy consulting practice of Deloitte Consulting LLP. From 2001 to 2009, she served as Chief Marketing Officer and President, Global Marketing for Bristol-Myers Squibb, where she served on the executive committee. From 1996 to 2001, she was Senior Vice President, Marketing at Merck & Co., a pharmaceutical company, with prior executive management positions at West Pharmaceuticals Services, Inc., Osteotech, Inc., and Centocor, Inc., and various positions at SmithKline & French Pharmaceuticals Co. (now GlaxoSmithKline) in marketing, regulatory affairs, project management and as a biochemist. Dr. Dixon has served on the boards of directors of publicly traded biopharmaceutical company Alkermes plc since January 2011, publicly traded biotechnology companies bluebird bio, Inc. since May 2013 and Eleven Biotherapeutics, Inc. since October 2014, and publicly traded pharmaceutical company Incyte Corporation since May 2010. She was formerly on the boards of directors of publicly traded companies Dentsply International, Inc., a dental company, from July 2005 to July 2010; Furiex Pharmaceuticals, Inc., a pharmaceutical company acquired by Actavis plc in 2014, from 2010 to 2014; Orexigen Therapeutics, Inc., a biopharmaceutical company, from April 2010 to January 2016; and Ardea Biosciences, Inc., a biopharmaceutical company acquired by AstraZeneca plc in 2012, from 2011 to 2012. Dr. Dixon received her B.Sc., M.Sc., and Ph.D. from the University of Cambridge (UK).

James Geraghty

Mr. James A. Geraghty is Independent Director of the Company. He also serves as chairman of the board of directors of Idera Pharmaceuticals, Inc., chairman of the board of directors of Juniper Pharmaceuticals, Inc., and a director of Fulcrum Therapeutics, Inc. He served as an Entrepreneur in Residence at Third Rock Ventures from May 2013 to October 2016. Prior to that, Mr. Geraghty served as Senior Vice President, North America Strategy and Business Development at Sanofi S.A. from February 2011 to October 2013. Earlier, he held many roles at Genzyme Corporation from 1992 to 2011, most recently as Senior Vice President of International Development and an executive officer. While at Genzyme, his roles included President of Genzyme Europe and General Manager of Genzyme’s cardiovascular business. He also served as Chairman, President and CEO of GTC Biotherapeutics, Inc. (formerly Genzyme Transgenics). Mr. Geraghty received a B.A. in Psychology and English from Georgetown University, M.S. in Clinical Psychology from the University of Pennsylvania, and a J.D. from Yale Law School.

Michael Higgins

Mr. Michael J. Higgins is an Independent Director of the Company. Mr. Higgins joined Polaris Partners as an entrepreneur-in-residence. Prior to joining Polaris Partners, Mr. Higgins served as Chief Operating Officer and Chief Financial Officer at Ironwood Pharmaceuticals, Inc. from 2003 through December 2014. Prior to his work at Ironwood, from 1997 through 2003, Mr. Higgins worked at Genzyme Corporation in a variety of leadership roles including Vice President, Corporate Finance and Vice President, Business Development. While at Genzyme, he was involved with multiple businesses including the Cell Therapy, Gene Therapy, and Orphan Disease business units. Previously, Mr. Higgins served as Chief Financial Officer of Procept, Inc., from 1992 to 1997. He also serves on the board of directors of Genocea Biosciences, Inc., Pulmatrix, Inc., KinDex Pharamaceuticals, Inc., Marauder Therapeutics, Inc., and Private Equity Access Fund, II. Mr. Higgins began his pharmaceutical career as a sales representative for Schering-Plough Corporation in 1986. Mr. Higgins earned his Bachelor of Science degree from Cornell University and holds an M.B.A. from the Amos Tuck School of Business at Dartmouth College. We believe Mr. Higgins’ financial and business expertise, including his diversified background as an executive officer in public pharmaceutical companies, qualifies him to serve as a member of the Board of Directors.

Steven Hyman

Dr. Steven Hyman, M.D. is an Independent Director of the Company. He has served as director of the Stanley Center for Psychiatric Research at the Broad Institute of Harvard and MIT and as a Core Faculty Member of the Broad Institute since February 2012. Dr. Hyman has served as a Harvard University Distinguished Service Professor of Stem Cell and Regenerative Biology since July 2011. From December 2001 to June 2011, he served as Provost of Harvard University, the University’s chief academic officer. From 1996 to 2001, he served as director of the U.S. National Institute of Mental Health, where he emphasized investment in neuroscience and emerging genetic technologies. He was elected to the Institute of Medicine in 2000, renamed the National Academy of Medicine, where he currently serves on the governing Council and chairs the Forum on Neuroscience and Nervous Systems Disorders, which brings together government, industry, patients groups, and academia. He serves on the governing board of the National Research Council, the operating arm of the U.S. National Academies. He is a fellow of the American Academy of Arts and Sciences, a fellow of the American Association for the Advancement of Science, a fellow and President-elect of the American College of Neuropsychopharmacology, and a Distinguished Life Fellow of the American Psychiatric Association. Dr. Hyman received a B.A. from Yale College, Summa Cum Laude, an M.A. from the University of Cambridge, which he attended as a Mellon fellow, and an M.D. from Harvard Medical School. We believe that Dr. Hyman’s extensive knowledge of neuroscience combined with his leadership skills qualifies him to serve as a member of the Board of Directors.

Perry Karsen

Mr. Perry A. Karsen is an Independent Director of the Company. Mr. Karsen was the Chief Executive Officer of the Celgene Cellular Therapeutics, Inc. division of Celgene Corporation, a publicly traded global biopharmaceutical company, from May 2013 until December 2015. Mr. Karsen served as Chief Operations Officer and Executive Vice President of Celgene from July 2010 to May 2013, and as senior vice president and head of worldwide business development of Celgene from 2004 to 2009. Between February 2009 and July 2010, Mr. Karsen was Chief Executive Officer of Pearl Therapeutics Inc., a privately held biotechnology company subsequently acquired by AstraZeneca plc. Prior to his tenure with Celgene, Mr. Karsen held executive positions at Human Genome Sciences, Inc., Bristol-Myers Squibb Co., a publicly traded biopharmaceutical company, Genentech, Inc. and Abbott Laboratories, a publicly traded pharmaceuticals and healthcare products company. In addition, Mr. Karsen served as a general partner at Pequot Ventures. He is a member of the Boards of Directors of Jounce Therapeutics, Inc., Intellia Therapeutics, Inc., and OncoMed Pharmaceuticals, Inc. Mr. Karsen was formerly a member of the boards of directors of the Biotechnology Innovation Organization (BIO) and the Alliance for Regenerative Medicine. Mr. Karsen received a Masters of Management degree from Northwestern University’s Kellogg Graduate School of Management, a Masters of Arts in Teaching of Biology from Duke University and a B.S. in Biological Sciences from the University of Illinois, Urbana-Champaign.

Basic Compensation

Name Fiscal Year Total

Mark Levin

129,858

G. Andre Turenne

--

Allison Dorval

--

Matthew Ottmer

2,829,380

Dinah Sah

--

Bernard Ravina

387,791

Glenn Pierce

364,944

Wendy Dixon

368,694

James Geraghty

142,608

Michael Higgins

149,858

Steven Hyman

136,858

Perry Karsen

144,358
As Of  31 Dec 2017